Found 15 clinical trials
Efficacy of Golimumab in Early Axial Spondyloarthritis in Relation to Gut Inflammation (GO-GUT)
The hypothesis of the study is that the presence of (subclinical) gut inflammation at baseline in patients with early active axial spondyloarthritis predisposes to a more severe disease defined as more need to use anti-tumor necrosis factor therapy and a shorter time to relapse after stopping anti-tumor necrosis factor therapy …
- 3 views
- 03 Feb, 2022
- 3 locations
A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis (AFFINITY)
The purpose of this study is to evaluate the efficacy of guselkumab plus golimumab combination treatment in participants with active psoriatic arthritis (PsA) and inadequate response (IR) to a
- 7 views
- 25 Jul, 2022
- 16 locations
Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis (ROC-SPA)
rheumatoid arthritis. Etanercept is a fusion protein with TNF receptor type II p75 and IgG1 Fc fragment, whereas adalimumab, infliximab, and golimumab are monoclonal antibodies. Certolizumab is a fusion
- 17 views
- 27 Feb, 2022
- 13 locations
A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (PURSUIT 2)
The purpose of this study is to evaluate efficacy of golimumab in inducing clinical remission as assessed by the Mayo score, in pediatric participants with moderately to severely active
- 53 views
- 11 Jul, 2022
- 50 locations
A Phase 2b Randomized, Double-blind, Active-and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD)
The purpose of this study is to evaluate the efficacy of JNJ-78934804 at Week 48 compared to guselkumab and golimumab.
- 0 views
- 20 Sep, 2022
- 3 locations
Golimumab for the Treatment of Refractory Behcet's Uveitis
The aim of this single-center prospective study is to evaluate the efficacy and safety of Golimumab （GOL）, fully humanized anti-tumor necrosis factor (TNF)-α monoclonal antibody, in the
- 31 views
- 16 May, 2022
- 1 location
Identification of Predictive Biomarkers for Response to Biologic Therapies in Inflammatory Bowel Disease
Prospective, multicentre trial which the biologic treatment will be initiated by clinical indication. The treatment selection anti-TNF (infliximab, adalimumab or golimumab), vedolizumab and
- 32 views
- 03 Sep, 2021
- 19 locations
EFFICACI : EFFicacy of Intravenous Infliximab Versus Vedolizumab After Failure of subCutaneous Anti-TNF in Patients With UlCerative Colitis (EFFICACI)
infliximab, adalimumab and golimumab) revolutionized the management of immune-mediated chronic diseases in the past two decades. However, about one third of patients will not respond to a first anti
- 22 views
- 16 Feb, 2022
- 15 locations
Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic Events
Post-authorization, prospective and unicenter clinical trial, in which patients with UC will be included. The treatment with anti-TNFα (infliximab, adalimumab or golimumab) or JAK-inhibitors
- 0 views
- 20 Aug, 2022
- 1 location
Assessing Patient Confidence in Biologic Medications
cycle. Examples of biologic medications commonly used in dermatology include tumor necrosis factor-alpha (TNF-alpha), blockers/inhibitors (etanercept, infliximab, certolizumab pegol, golimumab
- 67 views
- 25 Apr, 2022
- 1 location
- 1
- 2